Jones Trading Downgrades Theravance Biopharma (TBPH) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Zymeworks to acquire Theravance Biopharma for $17 per share
June 29, 2026 6:01 AM EDTZymeworks Inc. has agreed to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH) for $17.00 per share in cash, representing an equity value of approximately $929 million, according to a press release issued June 29, 2026.
Theravance Biopharma shareholders will also receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture, or other... More
Zymeworks to buy Theravance Biopharma for $17 per share
June 29, 2026 6:00 AM EDTZymeworks Inc. (NASDAQ: ZYME) announced it has entered into a definitive agreement to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH) at $17.00 per share in cash, representing a total transaction value of approximately $929 million, subject to customary adjustments.
The acquisition adds YUPELRI (revefenacin), a nebulized long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease,... More
